Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HRH4 | Q9H3N8 | 12/20 | 0.49 |
| ▸ | TLR8 | Q9NR97 | 1/20 | 0.46 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.44 |
| ▸ | LMNA | P02545 | 1/20 | 0.43 |
| ▸ | HTT | P42858 | 1/20 | 0.43 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.43 |
| ▸ | AURKA | O14965 | 1/20 | 0.43 |
| ▸ | PDPK1 | O15530 | 1/20 | 0.43 |
| ▸ | TGFBR1 | P36897 | 1/20 | 0.43 |
| ▸ | AURKB | Q96GD4 | 1/20 | 0.43 |
| ▸ | XDH | P47989 | 1/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.39 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.39 |
| ▸ | RAB9A | P51151 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15757792 | 0.82 | NUDT1 (0.56) | HRH4TLR8HSD17B10LMNAHTT | |
| SCHEMBL1318840 | 0.73 | PDPK1 (0.66) | HRH4AURKAPDPK1TGFBR1AURKB | |
| SCHEMBL15757289 | 0.72 | NUDT1 (0.58) | HRH4TLR8AURKAPDPK1TGFBR1 | |
| SCHEMBL28043950 | 0.72 | MAPT (0.43) | HRH4TLR8LMNAHTTAURKA | |
| SCHEMBL4765998 | 0.70 | CYP3A4 (0.46) | HSD17B10KDM4ERAB9A | |
| SCHEMBL28043771 | 0.70 | HRH4 (0.62) | HRH4TLR8 | |
| SCHEMBL28151149 | 0.69 | HRH4 (0.64) | HRH4TLR8AURKAPDPK1TGFBR1 | |
| SCHEMBL28043933 | 0.69 | HRH4 (0.50) | HRH4TLR8 | |
| SCHEMBL28151182 | 0.69 | HRH4 (0.52) | HRH4TLR8 | |
| SCHEMBL28267209 | 0.68 | TLR8 (0.46) | HRH4TLR8AURKAPDPK1TGFBR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9604937-B2 | Pyrimidine-2,4-diamine derivatives for treatment of cancer | THOMAS HELLEDAYS STIFTELSE FOR MEDICINSK FORSKNING (SE) | 2017-03-28 | — | — | US | disclosed |
| US-20160002175-A1 | Pyrimidine-2,4-Diamine Derivatives for Treatment of Cancer | THOMAS HELLEDAYS STIFTELSE FOR MEDICINSK FORSKNING (SE) | 2016-01-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160002175-A1 | Pyrimidine-2,4-Diamine Derivatives for Treatment of Cancer | DPYD, MTHFD1, TYMS | HRH4 2495/4885TLR8 4550/4885HSD17B10 890/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.